What is Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (300204.SZ) StockRank?

MoatMap's StockRank for Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) is 16/100, with a Strong Sell signal. This is a composite score combining Quality (33), Value (36), and Momentum (35) factor ranks across MoatMap's 19,000+ stock universe.

Does Staidson (Beijing) BioPharmaceuticals Co., Ltd. have an economic moat?

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Staidson (Beijing) BioPharmaceuticals Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Staidson (Beijing) BioPharmaceuticals Co., Ltd. in?

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300204.SZ

STRONG SELLREMOVE

Staidson (Beijing) BioPharmaceuticals Co., Ltd. · Healthcare · China · $1.8B · Avg Vol: $76M/d

StockRank

P/E (TTM)

—

ROE

-10.7%

D/E

0.2x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Staidson BioPharma lacks a clear connection to our core CDMO pricing power theme, and its weak quality metrics (Q-score of 33) make it an unsuitable candidate for a concentrated quality-focused portfolio.

COMPANY DESCRIPTION

Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a biopharmaceutical company focused on the research, development, and commercialization of therapeutic biological products. Its flagship product, Mouse Nerve Growth Factor, is a market-leading treatment for peripheral nerve damage in China. The company's competitive moat is sustained by its proprietary bioprocess technologies, strong clinical track record, and specialized sales network in neurology and orthopedics.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	81M	54M	48M	33M	-26.2%
EPS	-0.06	-0.12	-0.04	-0.02	—
Shares	475M	478M	478M	478M	+0.5%
Debt	867,215	4M	4M	12M	140.0%
Equity	200M	151M	137M	121M	-15.4%
Op CF	-26M	-34M	-9M	-19M	—
Inv CF	47M	3M	622,669	-8M	—
Fin CF	5M	5M	4M	37M	—

PRICE (1M)-24.9%

SMA 50SMA 200

$3.07

RSI (14)

35.4

52W High

$9.85

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

-7.3%36.6

ROE

-10.7%35.0

GP/Assets

12.5%30.6

Op. Margin

-11.9%28.8

FCF/Assets

-13.0%24.5

Piotroski

—7.2

Int. Cover

-9.4x25.4

D/E Ratio

0.15x58.3

Current Ratio

2.00x36.8

Value

P/E (TTM)

—N/A

EV/EBITDA

-164.3x97.9

P/FCF

—N/A

P/B

12.2x8.3

P/S

48.6x10.4

Div Yield

—N/A

Momentum

52W High %

31%6.1

RS 6M

-33%37.4

SMA 50/200

0.86x23.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—96.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.8B

P/E (Forward)

26.9x

Gross Margin

77.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300204.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300204.SZ	Staidson (Beijing) BioPharmaceuticals Co., Ltd.(you)	$1.8B	16	STRONG SELL
2616.HK	CStone Pharmaceuticals	$1.6B	14	STRONG SELL
688382.SS	InventisBio Co., Limited	$1.7B	12	STRONG SELL
688443.SS	Chongqing Genrix Biopharmaceutical Co., Ltd.	$1.5B	12	STRONG SELL
300294.SZ	China Resources Boya Bio-pharmaceutical Group Co.,Ltd	$1.2B	16	STRONG SELL
9688.HK	Zai Lab Limited	$2.0B	22	SELL
2595.HK	GenFleet Therapeutics (Shanghai) Inc.	$1.6B	21	SELL
1672.HK	Ascletis Pharma Inc.	$1.9B	25	SELL
688068.SS	Beijing Hotgen Biotech Co., Ltd.	$1.2B	12	STRONG SELL
9606.HK	Duality Biotherapeutics, Inc.	$2.6B	11	STRONG SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.0%

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) — Stock Score Summary

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) has a MoatMap StockRank of 16/100 based on Quality (33/100), Value (36/100), and Momentum (35/100) factor scores. The current signal is STRONG SELL. Staidson BioPharma lacks a clear connection to our core CDMO pricing power theme, and its weak quality metrics (Q-score of 33) make it an unsuitable candidate for a concentrated quality-focused portfolio.

Key Financial Metrics

Price	$3.07
Market Cap	$1.8B
P/E (Forward)	26.92
Price/Book	12.23
Return on Equity	-10.7%
Return on Invested Capital	-7.3%
Debt/Equity	15.07
Gross Margin	77.1%
Operating Margin	-11.9%
Revenue Growth	-25.8%
Free Cash Flow	$-4M

Staidson (Beijing) BioPharmaceuticals Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Staidson (Beijing) BioPharmaceuticals Co., Ltd.’s (300204.SZ) StockRank?: MoatMap’s StockRank for Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) is 16/100, with a Strong Sell signal. It is a composite of Quality (33), Value (36), and Momentum (35) factor ranks across MoatMap’s 19,000+ stock universe.
Does Staidson (Beijing) BioPharmaceuticals Co., Ltd. have an economic moat?: Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Staidson (Beijing) BioPharmaceuticals Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Staidson (Beijing) BioPharmaceuticals Co., Ltd. in?: Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).